Equities

InventisBio Co Ltd

688382:SHH

InventisBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.38
  • Today's Change-0.48 / -4.42%
  • Shares traded10.54m
  • 1 Year change-37.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.

  • Revenue in CNY (TTM)77.51m
  • Net income in CNY-348.02m
  • Incorporated2013
  • Employees221.00
  • Location
    InventisBio Co LtdNo.4 Building, Lane 67, Libing RoadSHANGHAI 201203ChinaCHN
  • Phone+86 2 150778527
  • Fax+86 2 150778527
  • Websitehttp://www.inventisbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688382:SHH since
announced
Transaction
value
Lyvgen Biopharma Holdings Ltd-AssetsDeal completed22 Oct 202422 Oct 2024Deal completed2.27%211.00k
Data delayed at least 15 minutes, as of Nov 14 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qingdao Vland Biotech INC1.26bn66.23m3.83bn1.57k57.552.22--3.030.26310.26315.026.830.4253.783.76805,143.803.255.785.097.8944.9846.137.6510.340.924811.630.290433.593.078.0515.56-0.650724.68-6.89
Hinova Pharmaceuticals Inc109.74k-210.18m3.91bn179.00--3.18--35,666.91-2.12-2.120.001112.440.000077.120.0805613.07-14.10-31.86-15.71-37.18-450.31---191,529.30-25,578.246.38--0.0457---100.00--2.44--124.37--
Bide Pharmatech Co Ltd1.10bn80.03m4.36bn846.0053.452.18--3.970.89830.898312.2521.980.46080.93594.511,298,144.003.34--3.82--40.11--7.25--4.59--0.0492--30.94---24.94------
Shanghai Aladdin Biochemical Tech Co Ltd497.71m103.71m4.51bn566.0036.634.34--9.060.44390.44391.983.750.31030.38189.08879,345.607.208.838.229.6161.5761.4923.2126.853.10113.470.278145.716.5519.36-7.489.9531.41--
Jiangsu Yahong Meditech Co Ltd149.71m-403.23m4.69bn394.00--2.25--31.30-0.7074-0.70740.26273.650.059816.646.92379,971.80-16.14-15.80-17.15-16.4878.6355.32-269.87-9,445.918.97--0.0599--52,594.79---62.42--64.28--
Beijing Kawin Technol Sha-hld Co Ltd1.42bn134.34m4.84bn584.0034.652.61--3.410.81750.81758.5310.870.57361.803.272,431,971.006.495.318.526.7681.8086.0211.318.102.91--0.14143.8221.7314.8739.7121.0425.01--
Beijing Sun-Novo Pharma Research Co Ltd1.16bn221.37m5.20bn1.39k23.504.60--4.501.981.9810.3310.100.607935.951.77844,377.1011.2512.9918.7621.7053.3053.9318.5021.341.8629.920.306810.7437.7647.2218.0854.9034.77--
Shanghai Medicilon Inc984.17m-276.79m5.45bn2.42k--2.32--5.54-2.01-2.017.2317.460.30296.901.27378,525.60-8.529.34-10.6611.730.644336.71-28.1214.932.64--0.114720.18-17.6833.26-109.82--23.60--
GemPharmatech Co Ltd677.34m139.41m5.88bn1.51k41.832.76--8.690.3430.3431.655.200.27034.542.06449,761.405.569.456.3911.1363.0470.2120.5828.164.74--0.050914.6820.4563.48-3.48--141.38--
HitGen Inc423.87m52.55m5.92bn452.00112.454.30--13.970.13140.13141.063.440.2487.104.55937,755.302.994.633.165.1051.2358.8912.0520.6616.1538.230.139119.1412.6419.6961.16-1.96-6.12--
InventisBio Co Ltd77.51m-348.02m6.26bn221.00--3.61--80.80-0.6064-0.60640.13463.010.0383--0.5855350,739.20-17.19---18.36--90.80---448.98------0.0138------41.26------
Data as of Nov 14 2024. Currency figures normalised to InventisBio Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

18.67%Per cent of shares held by top holders
HolderShares% Held
HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 202418.59m4.65%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 202418.18m4.55%
Rongtong Fund Management Co., Ltd.as of 30 Jun 20247.23m1.81%
Penghua Fund Management Co., Ltd.as of 30 Jun 20247.21m1.80%
Bank of China Investment Management Co., Ltd.as of 30 Jun 20246.18m1.55%
CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 20245.34m1.34%
China Asset Management Co., Ltd.as of 30 Jun 20244.33m1.08%
GF Fund Management Co., Ltd.as of 30 Jun 20243.74m0.94%
Guotai Asset Management Co., Ltd.as of 30 Jun 20242.21m0.55%
Harvest Fund Management Co., Ltd.as of 30 Jun 20241.63m0.41%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.